LeonaBio, Inc.

LONASEC EDGAR

Biological Products, (No Diagnostic Substances)CIK: 1620463

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Research and Development Expense	$93.8M	$61.5M	$42.8M	$13.3M	$3.8M
Operating Income (Loss)	-$125.5M	-$104.0M	-$64.0M	-$20.0M	-$5.4M
Interest Expense	—	—	—	$367.0K	$346.0K
Nonoperating Income (Expense)	—	—	—	-$1.3M	-$466.0K
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest	—	—	—	—	-$5.2M
Net Income (Loss) Attributable to Parent	-$117.7M	-$95.6M	-$54.9M	-$20.0M	-$5.2M
Earnings Per Share, Basic	-$3.09	-$2.53	-$1.49	—	—
Earnings Per Share, Diluted	-$3.09	-$2.53	-$1.49	—	—

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$160.2M	$258.2M	$332.0M	$279.6M	$2.2M
Assets, Current	$154.7M	$207.5M	$260.8M	$192.3M	$2.2M
Cash and Cash Equivalents, at Carrying Value	$90.6M	$96.0M	$110.5M	$60.6M	$2.1M
Liabilities	$30.1M	$23.0M	$10.9M	$5.3M	$4.9M
Liabilities, Current	$28.8M	$21.4M	$9.3M	$4.4M	$1.3M
Accounts Payable, Current	$129.0K	$2.5M	$567.0K	$1.2M	$421.0K
Stockholders' Equity Attributable to Parent	$235.1M	$321.1M	$274.3M	-$19.7M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$100.8M	-$72.5M	-$43.1M	-$24.1M	-$3.7M
Net Cash Provided by (Used in) Investing Activities	$95.1M	$57.7M	-$4.1M	-$210.1M	$1.5M
Net Cash Provided by (Used in) Financing Activities	$493.0K	$654.0K	$97.1M	$292.8M	$946.0K
Payments to Acquire Property, Plant, and Equipment	$304.0K	$1.1M	$1.6M	$2.3M	$2.3M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)